NCT04094610 2025-11-19
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
16 trialsNCT04105270 2025-09-11
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT06931119 2025-04-17
Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients
Rabin Medical Center
Phase 1 Not yet recruiting
NCT02629692 2024-07-31
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Sun Pharma Advanced Research Company Limited
Phase 1/2 Active not recruiting
NCT04942730 2024-05-07
FluBuBe
St. Petersburg State Pavlov Medical University
Phase 2 Completed
NCT04336124 2022-11-28
Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients
TaiRx, Inc.
Phase 1 Completed
NCT04727138 2022-05-16
3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546
Exscientia AI Limited
Phase 1 Completed
NCT03549650 2022-03-04
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Terminated
NCT03400306 2021-12-08
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
AbbVie
Phase 1 Withdrawn
NCT03469310 2021-05-11
Minimizing Narcotic Analgesics After Endocrine Surgery
DHR Health Institute for Research and Development
Phase 4 Completed
NCT03774680 2019-10-10
Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer
Al-Azhar University
Phase 1 Unknown
NCT01149720 2019-02-12
Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Completed
NCT02756663 2016-11-08
PANORAMA-5
Novartis
Phase 2 Withdrawn
NCT02536391 2016-11-02
Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects
Genentech, Inc.
Phase 1 Completed
NCT00390806 2014-01-20
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
GlaxoSmithKline
Phase 3 Completed
NCT00698516 2012-03-27
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed